On November 10, 2025, BioCardia, Inc. announced the enrollment of the first patient at Henry Ford Health for its Phase 3 CardiAMP HF II clinical trial focusing on ischemic heart failure with reduced ejection fraction. This is a significant event as it marks progress in their clinical studies.